Less than a tenth of people who could benefit from obesity jabs including Wegovy have access to them, caution the WHO as it issues its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.
Based on projections, over two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to widespread access to the treatments that can help people shift substantial body mass, notes the organization.
Skinny Jab Shortage
Even in the current most favorable case, the manufacturing of such drugs could only cover around 100 million people – less than 10% of those who need them, as stated by the health organization.
The advice calls on countries and companies to widen access, through strategies such as patent sharing.
Exclusive production rights on a key compound – the main component of a leading brand – is set to lapse in a number of countries in 2026.
How Weight-Loss Injections Operate
These medications imitate a biological compound to slow digestion, suppress the appetite and boost feelings of fullness so individuals reduce food intake.
Individuals commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Studies indicates people may put most of the weight back on within a year of discontinuing the drug, when their typical hunger come back.
Being overweight or obese increases your likelihood for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the WHO.
